Company profile: Sano
1.1 - Company Overview
Company description
- Provider of a small wearable sensor that continuously captures and transmits blood chemistry data to virtually any device and liberates this data to a third-party development and analytical platform called the 'API for the bloodstream'.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sano
SmartCells
HQ: United States
Website
- Description: Provider of insulin and polymer-based products for diabetes, including SmartInsulin, a self-regulating injectable formulation, and polymer-based dosing technology for applications in fertility, thyroid, and growth hormone deficiencies, and treatments with poor compliance or therapeutic window.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartCells company profile →
Kaleido
HQ: The Netherlands
Website
- Description: Provider of wearable insulin pump solutions for diabetes management, including the Kaleido insulin pump delivering continuous fast-acting insulin over 24 hours with hourly adjustments, connecting via a tube and infusion set and wearable up to three days; the Kaleido with Diabeloop’s DBLG1 Hybrid Closed Loop using Dexcom G6 and a handheld device to auto-adjust dosing; and a starter kit with two reusable pumps, a handset, training and support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaleido company profile →
Akston Biosciences
HQ: United States
Website
- Description: Provider of novel biologics developed and manufactured via a fusion protein platform, offering veterinary therapies: once-weekly insulin for diabetic dogs and cats; a FcRn-recycled GLP-1 weekly therapy for cats addressing diabetes and obesity; canine and feline oncology treatments via growth factor receptor downregulation; and a canine therapeutic vaccine targeting NGF for chronic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akston Biosciences company profile →
Alantos
HQ: United States
Website
- Description: Provider of chemistry-driven biopharmaceutical discovery and development of small molecule drugs for osteoarthritis, inflammation, and type II diabetes; offerings include tissue remodeling pathways for rheumatoid arthritis and a dipeptidyl peptidase IV inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alantos company profile →
Satiogen
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies targeting type 2 diabetes, offering metabolic mechanism therapy designed to regulate nutrient intake and postprandial glucose. Products include a substitute for metformin in gliptin formulations and an OTC nutraceutical.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satiogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sano
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sano
2.2 - Growth funds investing in similar companies to Sano
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sano
4.2 - Public trading comparable groups for Sano
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →